NasdaqGS:UTHRBiotechs
United Therapeutics Ralinepag Data Reshapes Pulmonary Hypertension And Valuation Story
United Therapeutics (NasdaqGS:UTHR) reported highly positive Phase 3 ADVANCE OUTCOMES trial results for ralinepag in pulmonary arterial hypertension.
The data showed strong efficacy and safety outcomes in patients enrolled in the study.
The company plans to submit a New Drug Application for ralinepag to the US FDA later this year.
United Therapeutics focuses on therapies for pulmonary arterial hypertension, a rare and serious cardiopulmonary condition with a significant unmet medical need...